Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 13/20 | 0.66 |
| ▸ | ADRA2B | P18089 | 12/20 | 0.66 |
| ▸ | ADRA2C | P18825 | 12/20 | 0.66 |
| ▸ | ADRA1D | P25100 | 9/20 | 0.66 |
| ▸ | ADRA1B | P35368 | 9/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 9/20 | 0.66 |
| ▸ | LMNA | P02545 | 4/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | HTR1A | P08908 | 2/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.66 |
| ▸ | BLM | P54132 | 2/20 | 0.66 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brimonidine SCHEMBL20511531 | 0.79 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL24670 | 0.79 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| SCHEMBL29171467 | 0.79 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| SCHEMBL11190309 | 0.79 | ADRA2A (0.56) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| SCHEMBL7028091 | 0.79 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| SCHEMBL3353162 | 0.79 | ADRA2A (0.71) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| SCHEMBL6054549 | 0.79 | ADRA2A (0.60) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL29374525 | 0.79 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL1685506 | 0.78 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL22616115 | 0.78 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CADRA1DADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020210889-A1 | DYE COMPOSITION FOR MARKING ORGANIC TISSUE WITH ANAESTHETIC AND METHOD FOR APPLYING SAME | HEXSEL, DORIS MARIA (BR) | 2020-10-22 | — | — | WO | claimed |
| EP-3434271-B1 | USE OF PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF POIKILODERMA OF CIVATTE | HEXSEL DORIS MARIA (BR) | 2020-08-26 | — | — | EP | claimed |
| US-10617688-B2 | Use of pharmaceutical composition for the treatment of skin erythema in poikilodermas | NOVA SCIENTIFICA LLC | 2020-04-14 | — | — | US | claimed |
| US-20190269680-A1 | USE OF AN ACTIVE SUBSTANCE IN THE TREATMENT OF MELASMA | HEXSEL DORIS MARIA (BR) | 2019-09-05 | — | — | US | claimed |
| EP-3476393-A1 | USE OF AN ACTIVE SUBSTANCE IN THE TREATMENT OF TELANGIECTATIC MELASMA | Hexsel, Doris Maria (BR) | 2019-05-01 | — | — | EP | claimed |
| US-20190111055-A1 | USE OF PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SKIN ERYTHEMA IN POIKILODERMAS | NOVA SCIENTIFICA LLC | 2019-04-18 | — | — | US | claimed |
| EP-3434271-A1 | USE OF PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SKIN ERYTHEMA IN POIKILODERMAS | Hexsel, Doris Maria (BR) | 2019-01-30 | — | — | EP | claimed |
| US-20160166569-A1 | METHOD FOR TREATING SKIN THICKENING | GALDERMA RESEARCH AND DEVELOPMENT (FR) | 2016-06-16 | — | — | US | claimed |
| EP-3024462-A2 | METHOD FOR TREATING SKIN THICKENING | Galderma Research & Development (FR) | 2016-06-01 | — | — | EP | claimed |
| US-20150313896-A1 | METHOD FOR TREATING CELL PROLIFERATION DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-11-05 | — | — | US | claimed |
| EP-2598129-A2 | USE OF ALPHA-ADRENERGIC RECEPTOR AGONIST FOR PREVENTING OR TREATING SKIN TUMOR | Galderma Research & Development (FR) | 2013-06-05 | — | — | EP | claimed |
| US-20130116259-A1 | COMBINATION THERAPY FOR TREATING OR PREVENTING AN INFLAMMATORY SKIN DISORDER | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-05-09 | — | — | US | claimed |
| EP-2501410-A2 | COMBINATION OF ALPHA-2 ADRENERGIC RECEPTOR AGONIST AND NON-STEROIDAL ANTI-INFLAMMATORY AGENT FOR TREATING OR PREVENTING AN INFLAMMATORY SKIN DISORDER | Galderma Research & Development (FR) | 2012-09-26 | — | — | EP | claimed |
| EP-2501373-A1 | USE OF ALPHA 2 ADRENERGIC RECEPTOR AGONISTS FOR TREATING OR PREVENTING PSORIASIS | Galderma Laboratories LP (US) | 2012-09-26 | — | — | EP | claimed |
| EP-2481412-A1 | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders | Galderma Pharma S.A. (CH) | 2012-08-01 | — | — | EP | claimed |
| WO-2012001065-A2 | METHOD FOR PREVENTING OR TREATING SKIN TUMOR | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-01-05 | — | — | WO | claimed |
| WO-2011075267-A1 | USE OF ALPHA 2 ADRENERGIC RECEPTOR AGONISTS FOR TREATING OR PREVENTING PSORIASIS | GALDERMA LABORATORIES LP (US) | 2011-06-23 | — | — | WO | claimed |
| EP-2329849-A1 | Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder | Galderma Research & Development (FR) | 2011-06-08 | — | — | EP | claimed |
| WO-2011061252-A2 | COMBINATION THERAPY FOR TREATING OR PREVENTING AN INFLAMMATORY SKIN DISORDER | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-05-26 | — | — | WO | claimed |
| US-20110118267-A1 | Method and Kit for Treating or Preventing Psoriasis | Galderma Laboratories, L.P. (US) | 2011-05-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166569-A1 | METHOD FOR TREATING SKIN THICKENING | CUTA, EDNRB, TBXA2R | ADRA2A 8/4885ADRA2B 9/4885ADRA2C 15/4885 |
| US-20150313896-A1 | METHOD FOR TREATING CELL PROLIFERATION DISORDERS | MKI67, ADRB1, ADRA1D | ADRA2A 8/4885ADRA2B 9/4885ADRA2C 16/4885 |
| US-20110118267-A1 | Method and Kit for Treating or Preventing Psoriasis | ADRB2, ADRA2A, ADRA2C | ADRA2A 2/4885ADRA2B 4/4885ADRA2C 3/4885 |
| US-20130116259-A1 | COMBINATION THERAPY FOR TREATING OR PREVENTING AN INFLAMMATORY SKIN DISORDER | ADRB2, ADRA2A, ADRA2C | ADRA2A 2/4885ADRA2B 4/4885ADRA2C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.